Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aclidinium | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Pipenzolate. |
| Mirabegron | The risk or severity of urinary retention can be increased when Pipenzolate is combined with Mirabegron. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Pipenzolate. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Pipenzolate. |
| Tiotropium | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Pipenzolate is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Umeclidinium. |
| Glycopyrronium | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Glycopyrronium. |
| Botulinum toxin type A | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Botulinum toxin type A. |
| Glucagon | Pipenzolate may increase the gastrointestinal motility reducing activities of Glucagon. |
| Sulpiride | Pipenzolate may increase the anticholinergic activities of Sulpiride. |
| Botulinum toxin type B | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Botulinum toxin type B. |
| Eluxadoline | The risk or severity of constipation can be increased when Pipenzolate is combined with Eluxadoline. |
| Ramosetron | The risk or severity of constipation can be increased when Pipenzolate is combined with Ramosetron. |
| Naltrexone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Naltrexone. |
| Bezitramide | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Bezitramide. |
| Tramadol | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Tramadol. |
| Morphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Morphine. |
| Codeine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Codeine. |
| Hydromorphone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Hydromorphone. |
| Methadone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Methadone. |
| Meperidine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Meperidine. |
| Oxycodone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Oxycodone. |
| Butorphanol | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Butorphanol. |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Dextropropoxyphene. |
| Pentazocine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Pentazocine. |
| Sufentanil | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Sufentanil. |
| Alfentanil | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Alfentanil. |
| Fentanyl | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Fentanyl. |
| Nalbuphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Nalbuphine. |
| Levorphanol | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Levorphanol. |
| Remifentanil | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Remifentanil. |
| Buprenorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Buprenorphine. |
| Hydrocodone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Hydrocodone. |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Diphenoxylate. |
| Oxymorphone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Oxymorphone. |
| Dezocine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Dezocine. |
| Levacetylmethadol | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Levacetylmethadol. |
| Methadyl acetate | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Methadyl acetate. |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Dihydroetorphine. |
| Diamorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Diamorphine. |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Ethylmorphine. |
| Etorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Etorphine. |
| Dextromoramide | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Dextromoramide. |
| Desomorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Desomorphine. |
| Carfentanil | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Carfentanil. |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Dihydrocodeine. |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Alphacetylmethadol. |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Dihydromorphine. |
| Tapentadol | The risk or severity of urinary retention and constipation can be increased when Pipenzolate is combined with Tapentadol. |
| Ketobemidone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Ketobemidone. |
| DPDPE | The risk or severity of adverse effects can be increased when Pipenzolate is combined with DPDPE. |
| Lofentanil | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Lofentanil. |
| Opium | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Opium. |
| Normethadone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Normethadone. |
| Piritramide | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Piritramide. |
| Alphaprodine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Alphaprodine. |
| Nicomorphine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Nicomorphine. |
| Meptazinol | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Meptazinol. |
| Phenoperidine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Phenoperidine. |
| Phenazocine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Phenazocine. |
| Tilidine | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Tilidine. |
| Carfentanil, C-11 | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Carfentanil, C-11. |
| Benzhydrocodone | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Benzhydrocodone. |
| Naloxegol | The risk or severity of adverse effects can be increased when Pipenzolate is combined with Naloxegol. |
| Trospium | The risk or severity of adverse effects can be increased when Trospium is combined with Pipenzolate. |
| Oxyphenonium | The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pipenzolate. |
| Benzatropine | The risk or severity of adverse effects can be increased when Benzatropine is combined with Pipenzolate. |
| Disopyramide | The risk or severity of adverse effects can be increased when Disopyramide is combined with Pipenzolate. |
| Metixene | The risk or severity of adverse effects can be increased when Metixene is combined with Pipenzolate. |
| Terfenadine | The risk or severity of adverse effects can be increased when Terfenadine is combined with Pipenzolate. |
| Buclizine | The risk or severity of adverse effects can be increased when Buclizine is combined with Pipenzolate. |
| Trihexyphenidyl | The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pipenzolate. |
| Oxyphencyclimine | The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Pipenzolate. |
| Procyclidine | The risk or severity of adverse effects can be increased when Procyclidine is combined with Pipenzolate. |
| Hyoscyamine | The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pipenzolate. |
| Methscopolamine bromide | The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Pipenzolate. |
| Darifenacin | The risk or severity of adverse effects can be increased when Darifenacin is combined with Pipenzolate. |
| Tridihexethyl | The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Pipenzolate. |
| Anisotropine methylbromide | The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Pipenzolate. |
| Atropine | The risk or severity of adverse effects can be increased when Atropine is combined with Pipenzolate. |
| Nicardipine | The risk or severity of adverse effects can be increased when Nicardipine is combined with Pipenzolate. |
| Mecamylamine | The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pipenzolate. |
| Pirenzepine | The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipenzolate. |
| Homatropine methylbromide | The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Pipenzolate. |
| Benzquinamide | The risk or severity of adverse effects can be increased when Benzquinamide is combined with Pipenzolate. |
| Propantheline | The risk or severity of adverse effects can be increased when Propantheline is combined with Pipenzolate. |
| Dicyclomine | The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipenzolate. |
| Tropicamide | The risk or severity of adverse effects can be increased when Tropicamide is combined with Pipenzolate. |
| Cocaine | The risk or severity of adverse effects can be increased when Cocaine is combined with Pipenzolate. |
| Quinidine | The risk or severity of adverse effects can be increased when Quinidine is combined with Pipenzolate. |
| Amantadine | The risk or severity of adverse effects can be increased when Amantadine is combined with Pipenzolate. |
| Methantheline | The risk or severity of adverse effects can be increased when Methantheline is combined with Pipenzolate. |
| Cycrimine | The risk or severity of adverse effects can be increased when Cycrimine is combined with Pipenzolate. |
| Cyclopentolate | The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pipenzolate. |
| Tolterodine | The risk or severity of adverse effects can be increased when Tolterodine is combined with Pipenzolate. |
| Oxybutynin | The risk or severity of adverse effects can be increased when Oxybutynin is combined with Pipenzolate. |
| Pentolinium | The risk or severity of adverse effects can be increased when Pentolinium is combined with Pipenzolate. |
| Trimethaphan | The risk or severity of adverse effects can be increased when Trimethaphan is combined with Pipenzolate. |